Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure-activity relationship

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2605-2608

  Rachid, Zakaria ^a   Brahimi, Fouad ^a   Qiu, Qiyu ^a   Williams, Christopher ^b   Hartley, Janet M ^c   Hartley, John A ^c   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MODELS, MOLECULAR; NITROGEN MUSTARD COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TRIAZENES;

EID: 34250219551     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070144p     Document Type: Article

References (15)

1. Matheson, S. L.; McNamee, J.; Jean-Claude, B. J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J. Pharmacol. Exp. Ther. 2001, 296, 832-840.
2. Ma, J.; Murphy, M.; O'Dwyer, P. J.; Berman, E.; Reed, K.; Gallo, J. M. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem. Pharmacol. 2002, 63, 1219-1228.
3. Pepponi, R.; Griaziani, G.; Falcinelli, S.; Vernole, P.; Levati, L.; Lacal, P. M.; Pagani, E.; Bonmassar, E.; Jiricny, J.; D'Arti, S. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis 2001, 22, 1131-1137.
4. Yin, J. H.; Yang, D. I.; Chou, H.; Thompson, E. M.; Xu, J.; Hsu, C. Y. Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in C6 glioma cells. J. Pharmacol. Exp. Ther. 2001, 297, 308-315.
5. Rachid, Z.; Brahimi, F.; Domarkas, J.; Jean-Claude, B. J. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorg. Med. Chem. Lett. 2005, 15, 1135-1138.
6. Rachid, Z.; Brahimi, F.; Katsoulas, A.; Teo, N.; Jean-Claude, B. J. The combi-targeting concept: chemical dissection of the dual targeting propereties of a series of combi-triazenes. J. Med. Chem. 2003, 46, 4313-4321.
7. Rewcastle, G. W.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D.; Winters, T. R.; Denny, W. A. Structure-activity relationships for methyl-amino-substituted derivatives of 4-[(3-bromophenyl)-amino]-6-(methylamino)-pyrido[3,4-d] pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 1998, 41, 742-751.
8. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Hairong, Z.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitor. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
9. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, J. R.; Denny, W. A. Tyrosine kinase inhibitors. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimidino[5,4-d]-pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 1820-1826.
10. Roth, G. A.; Tai, J. J. A new synthesis of aryl substituted quinazolin-4(1H)-ones. J. Heterocycl. Chem. 1996, 33, 2051-2053.
11. MOE software (version 2006.07) available from Chemical Computing Group Inc., 1010 Sherbrooke Street West, Montreal, Quebec, Canada; www.chemcomp.com.
12. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
13. Brahimi, F.; Rachid, Z.; McNamee, J. P.; Alaoui-jamali, M. A.; Tari, A. M.; Jean-Claude, B. J. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem. Pharmacol. 2005, 70 (4), 511-519.
14. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; Mc Mahon, J.; Vistica, D. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
15. Spanswick, V. J.; Hartley, J. M.; Ward, T. H.; Hartley, J. A. Measurement of Drug-Induced DNA Interstrand Crosslinking Using the Single Cell Gel Electrophoresis (Comet) Assay. In Cytotoxic Drug Resistance Mechanisms; Brown, R., Boger-Brown, U., Eds.; Methods in Molecular Medicine, Vol. 28; Humana Press: Totowa, NJ, 1999; pp 143-154.